VitaDAO, a decentralized autonomous organization (DAO) with a focus on extending human life, has announced its foray into the field of biotechnology. Today marks the launch of Matrix Biosciences, a new biotech company established in partnership with renowned biologist Vera Gorbunova.
Matrix Biosciences, unlike the decentralized nature of VitaDAO, will operate as a centralized entity, embracing traditional corporate structures. VitaDAO will hold the majority of shares, ensuring accountability through quarterly reports—a significant departure from typical DAO practices.
The primary objective behind Matrix Biosciences is to bridge the gap between blockchain technology and the biotech industry, demonstrating the effective coexistence of these two domains. Todd White, a key member of VitaDAO, emphasized the importance of translating research conducted within a DAO into real-world applications.
Recognizing the stringent regulatory landscape in healthcare and medicine, VitaDAO and Matrix Biosciences are proactively collaborating with regulators to establish a strong foothold in the industry, dispelling any doubts about their commitment to responsible innovation.
Eleanor Davies, another core member of VitaDAO, highlighted the company’s pioneering mission. Matrix Biosciences will focus its research on the naked mole-rat, a long-lived rodent known for its high molecular weight hyaluronic acid (HMW-HA), which possesses anti-cancer, anti-pain, and pro-longevity properties. This research aims to harness the unique characteristics of these rodents to develop innovative solutions for cancer treatment and age-related diseases in humans.
Matrix Biosciences aligns perfectly with VitaDAO’s mission to fund “moonshot bleeding-edge research” that often falls outside the scope of traditional funding sources. The goal is to create groundbreaking therapeutics that redefine medical standards.
Lead scientist Vera Gorbunova, a world-renowned biologist, co-director of the University of Rochester’s Aging Research Center, and pioneer in the mechanisms of longevity and genome stability, will spearhead Matrix Biosciences’ research efforts.
With initial funding of $300,000 from VitaDAO and plans for further capital infusion through its IP-NFT fractionalization model, Matrix Biosciences signals a bold step towards revolutionizing biotech. Today’s launch sends a resounding message to the biotech community: VitaDAO is dedicated to pushing the boundaries of science and innovation in the quest to combat cancer and extend human life.
Pfizer Ventures is among the contributors to VitaDAO, initially providing $300,000 in funding for Matrix Biosciences. This venture plans to secure additional capital through its IP-NFT fractionalization model, solidifying its commitment to pushing the boundaries of biotech innovation.
Today’s launch sends a resounding message to the biotech community: VitaDAO is on a determined mission to combat aging and elevate human life, firmly grounded in scientific rigor and ethical responsibility.